 CHARLOTTESVILLE, VA ACCESSWIRE June 9, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW Adial or the Company, a biopharmaceutical company focused on the development of treatments for addiction and currently conducting the ONWARDTM pivotal Phase 3 clinical trial of its lead drug candidate, AD04, for the treatment of Alcohol Use Disorder, today announced that it has entered into a securities purchase agreement with institutional investors to purchase approximately 5.2 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement. The combined purchase price for one share of common stock and a warrant to purchase 0.75 shares of common stock will be 1.85. 